Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria
Intermittent preventive treatment (IPT) is increasingly used to reduce malaria morbidity and mortality in children and pregnant women. The efficacy of IPT depends on the pharmacokinetic and pharmacodynamic properties of the antimalarial drugs used. Healthy adult male volunteers whose occupation put...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826260245194735616 |
|---|---|
| author | Lwin, K Phyo, A Tarning, J Hanpithakpong, W Ashley, E Lee, S Cheah, P Singhasivanon, P White, N Lindegårdh, N Nosten, F |
| author_facet | Lwin, K Phyo, A Tarning, J Hanpithakpong, W Ashley, E Lee, S Cheah, P Singhasivanon, P White, N Lindegårdh, N Nosten, F |
| author_sort | Lwin, K |
| collection | OXFORD |
| description | Intermittent preventive treatment (IPT) is increasingly used to reduce malaria morbidity and mortality in children and pregnant women. The efficacy of IPT depends on the pharmacokinetic and pharmacodynamic properties of the antimalarial drugs used. Healthy adult male volunteers whose occupation put them at high risk of malaria on the Northwest border of Thailand were randomized to receive a 3-day-treatment dose of dihydroartemisinin-piperaquine monthly (DPm) or every 2 months (DPalt) or an identical placebo with or without fat (6.4g/dose) over a 9-month period. All volunteers were monitored weekly. One thousand adults were recruited. Dihydroartemisinin-piperaquine was well tolerated. There were 114 episodes of malaria (49 Plasmodium falciparum, 63 P. vivax, and 2 P. ovale). The protective efficacy against all malaria at 36 weeks was 98% (95% confidence interval [CI], 96% to 99%) in the DPm group and 86% (95% CI, 81% to 90%) in the DPalt group (for both, P < 0.0001 compared to the placebo group). As a result, the placebo group also had lower hematocrits during the study (P < 0.0001). Trough plasma piperaquine concentrations were the main determinant of efficacy; no malaria occurred in participants with a trough concentration above 31 ng/ml. Neither plasma piperaquine concentration nor efficacy was influenced by the coadministration of fat. DPm is safe to use and is effective in the prevention of malaria in adult males living in an area where P. vivax and multidrug-resistant P. falciparum malaria are endemic. Copyright © 2012, American Society for Microbiology. All Rights Reserved. |
| first_indexed | 2024-03-06T19:02:35Z |
| format | Journal article |
| id | oxford-uuid:140b4576-5da5-4ba0-b703-3c91b7a1fea0 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:02:35Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:140b4576-5da5-4ba0-b703-3c91b7a1fea02022-03-26T10:17:26ZRandomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malariaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:140b4576-5da5-4ba0-b703-3c91b7a1fea0EnglishSymplectic Elements at Oxford2012Lwin, KPhyo, ATarning, JHanpithakpong, WAshley, ELee, SCheah, PSinghasivanon, PWhite, NLindegårdh, NNosten, FIntermittent preventive treatment (IPT) is increasingly used to reduce malaria morbidity and mortality in children and pregnant women. The efficacy of IPT depends on the pharmacokinetic and pharmacodynamic properties of the antimalarial drugs used. Healthy adult male volunteers whose occupation put them at high risk of malaria on the Northwest border of Thailand were randomized to receive a 3-day-treatment dose of dihydroartemisinin-piperaquine monthly (DPm) or every 2 months (DPalt) or an identical placebo with or without fat (6.4g/dose) over a 9-month period. All volunteers were monitored weekly. One thousand adults were recruited. Dihydroartemisinin-piperaquine was well tolerated. There were 114 episodes of malaria (49 Plasmodium falciparum, 63 P. vivax, and 2 P. ovale). The protective efficacy against all malaria at 36 weeks was 98% (95% confidence interval [CI], 96% to 99%) in the DPm group and 86% (95% CI, 81% to 90%) in the DPalt group (for both, P < 0.0001 compared to the placebo group). As a result, the placebo group also had lower hematocrits during the study (P < 0.0001). Trough plasma piperaquine concentrations were the main determinant of efficacy; no malaria occurred in participants with a trough concentration above 31 ng/ml. Neither plasma piperaquine concentration nor efficacy was influenced by the coadministration of fat. DPm is safe to use and is effective in the prevention of malaria in adult males living in an area where P. vivax and multidrug-resistant P. falciparum malaria are endemic. Copyright © 2012, American Society for Microbiology. All Rights Reserved. |
| spellingShingle | Lwin, K Phyo, A Tarning, J Hanpithakpong, W Ashley, E Lee, S Cheah, P Singhasivanon, P White, N Lindegårdh, N Nosten, F Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria |
| title | Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria |
| title_full | Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria |
| title_fullStr | Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria |
| title_full_unstemmed | Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria |
| title_short | Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria |
| title_sort | randomized double blind placebo controlled trial of monthly versus bimonthly dihydroartemisinin piperaquine chemoprevention in adults at high risk of malaria |
| work_keys_str_mv | AT lwink randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria AT phyoa randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria AT tarningj randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria AT hanpithakpongw randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria AT ashleye randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria AT lees randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria AT cheahp randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria AT singhasivanonp randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria AT whiten randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria AT lindegardhn randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria AT nostenf randomizeddoubleblindplacebocontrolledtrialofmonthlyversusbimonthlydihydroartemisininpiperaquinechemopreventioninadultsathighriskofmalaria |